Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 43

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Irritable bowel syndrome

Not yet recruiting

Efficacy and Safety of Amara‑Tropfen Dilution vs Placebo in Patients with Irritable Bowel Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Weleda AG

Adenocarcinoma pancreas

Not yet recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Malignant peritoneal neoplasm+2

Not yet recruiting

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Small intestine adenocarcinoma

Not yet recruiting

Randomized trial of irinotecan drug combination versus standard therapy as first-line treatment in patients with locally advanced or metastatic small bowel adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Adenoid cystic carcinoma of salivary gland

Not yet recruiting

Efficacy and safety of lutetium‑177 vipivotide tetraxetan with gozetotide in patients with progressive adenoid cystic carcinoma of the salivary glands

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Adenocarcinoma gastric+3

Not yet recruiting

Study of immune response and biomarkers in patients with metastatic solid tumors treated with BMS-986340 and nivolumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bms-986340
  • Sponsor:Humanitas Mirasole S.p.A.

Gastric cancer

Not yet recruiting

Immune Modulation Study of Rilvegostomig and Pembrolizumab in Patients with Advanced Gastric Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Gastric cancer+1

Not yet recruiting

Capecitabine drug combination in perioperative treatment for patients with gastric and esophageal cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Colorectal adenocarcinoma

Not yet recruiting

Safety, Dose‑Finding and Feasibility Study of CD30/CEA CART in Patients with Liver Metastases from CEA‑Positive Colorectal Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Universitaetsklinikum Regensburg AöR

Squamous cell carcinoma of the oral cavity+1

Not yet recruiting

Study of neoadjuvant intratumoral ipilimumab combined with systemic nivolumab in patients with locally advanced resectable oral cavity squamous cell carcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Amsterdam UMC Stichting

Colorectal cancer

Not yet recruiting

Conversion intraperitoneal chemotherapy with oxaliplatin plus drug combination in colorectal cancer with peritoneal metastases unsuitable for upfront surgery or HIPEC

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Uppsala University Hospital

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.